Cystic fibrosis: Detecting changes in airway inflammation with FDG PET/CT

Radiology

Volumn 264, Issue 3, 2012, Pages 868-875

  Amin, Reshma ^a   Charron, Martin ^a   Grinblat, Leonard ^b   Shammas, Amer ^a   Grasemann, Hartmut ^a   Graniel, Karla ^c,d   Ciet, Pierluigi ^c,d   Tiddens, Harm ^c,d   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NORTH YORK GENERAL HOSPITAL   (Canada)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; NEUTROPHIL COUNT; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SCHOOL CHILD; SCORING SYSTEM; SPUTUM;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; LUNG; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RESPIRATORY FUNCTION TESTS;

EID: 84865405514     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111873     Document Type: Article

References (52)

1. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997;24(2):137-142; discussion 159-161.
2. Goss CH, Burns JL. Exacerbations in cystic fibrosis. I. Epidemiology and pathogenesis. Thorax 2007;62(4):360-367.
3. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151(4):1075-1082.
4. Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 2008;133(2):489-495.
5. Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax 2006;61(2):155-157.
6. Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002;165(7):904-910.
7. Nixon GM, Armstrong DS, Carzino R, et al. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002;87(4):306-311.
8. Wainwright CE, Grimwood K, Carlin JB, et al. Safety of bronchoalveolar lavage in young children with cystic fibrosis. Pediatr Pulmonol 2008;43(10):965-972.
9. Ordoñez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168(12):1471-1475.
10. Ciet P, Serra G, Bertolo S, et al. Diffusion-weighted imaging (DWI): a new method to detect active lung inflammation in cystic fibrosis? [abstr]. In: Radiological Society of North America Scientific Assembly and Annual Meeting Program. Oak Brook, Ill: Radiological Society of North America, 2010, 462.
11. Labiris NR, Nahmias C, Freitag AP, Thompson ML, Dolovich MB. Uptake of 18fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation? Eur Respir J 2003;21(5):848-854.
12. Chen DL, Schuster DP. Imaging pulmonary inflammation with positron emission tomography: a biomarker for drug development. Mol Pharm 2006;3(5):488-495.
13. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32(1):47-59.
14. Chen DL, Rosenbluth DB, Mintun MA, Schuster DP. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol 2006;100(5):1602-1609.
15. Chacko TK, Zhuang H, Nakhoda KZ, Moussavian B, Alavi A. Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection. Nucl Med Commun 2003;24(6):615-624.
16. Chen DL, Ferkol TW, Mintun MA, Pittman JE, Rosenbluth DB, Schuster DP. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med 2006;173(12):1363-1369.
17. Czernin J, Schelbert H. PET/CT imaging: facts, opinions, hopes, and questions. J Nucl Med 2004;45(Suppl):1S-3S.
18. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. RadioGraphics 2004;24(2):523-543.
19. Freeman L, Blaufox M. Letter from the editors. Semin Nucl Med 2004;34(2):83.
20. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. RadioGraphics 2004;24(5):1411-1431.
21. Mettler F, Guiberteau M. Essentials of nuclear medicine imaging. Philadelphia, Pa: Saunders Elsevier, 2006; 391.
22. Klein M, Cohen-Cymberknoh M, Armoni S, et al. 18F-fluorodeoxyglucose-PET/ CT imaging of lungs in patients with cystic fibrosis. Chest 2009;136(5):1220- 1228.
23. Henkin R, ed. Nuclear medicine. Philadelphia, Pa: Mosby Elsevier, 2006.
24. Brody AS, Kosorok MR, Li Z, et al. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J Thorac Imaging 2006;21(1):14-21.
25. Ordoñez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001;32(1):29-37.
26. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26(2):319-338.
27. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008;177(3):253-260.
28. Statistical considerations for a parallel trial where the outcome is a measurement. http://hedwig.mgh.harvard.edu/sample-size/js/js-parallel-quant. html.
29. Tateishi U, Hasegawa T, Seki K, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organising pneumonia: semi-quantitative evaluation using computed tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33(8):906-912.
30. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5(4):584-590.
31. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3(1):1-7.
32. Dolovich MB, Schuster DP. Positron emission tomography and computed tomography versus positron emission tomography computed tomography: tools for imaging the lung. Proc Am Thorac Soc 2007;4(4):328-333.
33. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996;37(6):950-955.
34. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004;45(9):1431-1434.
35. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45(9):1519-1527.
36. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145(1):32-38.
37. de Jong PA, Nakano Y, Hop WC, et al. Changes in airway dimensions on computed tomography scans of children with cystic fibrosis. Am J Respir Crit Care Med 2005;172(2):218-224.
38. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23(1):93-97.
39. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing wholebody dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005;46(4):608-613.
40. Mayo JR, Aldrich J, Muller NL; Fleischner Society. Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology 2003;228(1):15-21.
41. Wu TH, Huang YH, Lee JJ, et al. Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging 2004;31(1):38-43.
42. Ware DE, Huda W, Mergo PJ, Litwiller AL. Radiation effective doses to patients undergoing abdominal CT examinations. Radiology 1999;210(3):645-650.
43. Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med 2007;357(22):2277-2284.
44. Stabin MG, Gelfand MJ. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998;42(2):93-112.
45. Lucaya J, Piqueras J, García-Peña P, Enríquez G, García-Macías M, Sotil J. Lowdose high-resolution CT of the chest in children and young adults: dose, cooperation, artifact incidence, and image quality. AJR Am J Roentgenol 2000;175(4):985-992.
46. de González AB, Kim KP, Samet JM. Radiation-induced cancer risk from annual computed tomography for patients with cystic fibrosis. Am J Respir Crit Care Med 2007;176(10):970-973.
47. de Jong PA, Mayo JR, Golmohammadi K, et al. Estimation of cancer mortality associated with repetitive computed tomography scanning. Am J Respir Crit Care Med 2005;173:199-203.
48. Tiddens HA. Chest computed tomography scans should be considered as a routine investigation in cystic fibrosis. Paediatr Respir Rev 2006;7(3):202-208.
49. Brenner DJ. Estimating cancer risks from pediatric CT: going from the qualitative to the quantitative. Pediatr Radiol 2002;32(4):228-3; discussion 242-244.
50. Fahey FH, Palmer MR, Strauss KJ, Zimmerman RE, Badawi RD, Treves ST. Dosimetry and adequacy of CT-based attenuation correction for pediatric PET: phantom study. Radiology 2007;243(1):96-104.
51. Ratib O, Beyer T. Whole-body hybrid PET/MRI: ready for clinical use? Eur J Nucl Med Mol Imaging 2011;38(6):992-995.
52. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143(10):1007-1017.